Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723683 | 0.74 | USP30 (0.53) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 | |
| SCHEMBL4762090 | 0.73 | AADAT (0.39) | RAB9ACYP2C9 | |
| SCHEMBL4762083 | 0.73 | AADAT (0.39) | RAB9ACYP2C9 | |
| SCHEMBL4721036 | 0.72 | PARP1 (0.47) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 | |
| SCHEMBL1720529 | 0.72 | ALDH1A1 (0.51) | HTT | |
| SCHEMBL26983216 | 0.68 | SMN1; SMN2 (0.53) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 | |
| SCHEMBL17826956 | 0.68 | SMN1; SMN2 (0.52) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 | |
| SCHEMBL19405228 | 0.68 | GRIN2B (0.60) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 | |
| SCHEMBL19405175 | 0.68 | PDE4B (0.63) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 | |
| SCHEMBL19404810 | 0.68 | SMN1; SMN2 (0.57) | PDE4BJAK2JAK1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-1989204-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007095628-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PDE4B 1039/4885JAK2 3121/4885JAK1 3981/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PDE4B 1039/4885JAK2 3121/4885JAK1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.